WHO stage IV, poor adherence at the start of second-line ART, CD4 count <100 cells/mm3 at the start of second-line ART, TB co-morbidity, and age >45 years were found to be significantly associated with second-line treatment failure. The gene discussed is CD4; the disease is tuberculosis.